Who makes Fondapariniux?

Fondapariniux is developed by Weill Medical College of Cornell University.

What development phase is Fondapariniux in?

Fondapariniux is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Fondapariniux

Weill Medical College of Cornell University · FDA-approved active Small molecule Quality 0/100

Fondaparinux, developed by Weill Medical College of Cornell University, is a marketed anticoagulant with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and well-documented efficacy. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Fondapariniux
Also known as	Arixtra
Sponsor	Weill Medical College of Cornell University
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Fondapariniux CI brief — competitive landscape report
Fondapariniux updates RSS · CI watch RSS
Weill Medical College of Cornell University portfolio CI